Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$272.18 USD

272.18
309,158

-4.62 (-1.67%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $272.29 +0.11 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Boston Scientific's Positive SCS Trial Aids Neuromodulation

by Zacks Equity Research

Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.

    Zacks Equity Research

    Medtronic's ITB Therapy Superior to CMM for PSS Reduction

    by Zacks Equity Research

    Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.

      Zacks Equity Research

      Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod

      by Zacks Equity Research

      Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.

        Zacks Equity Research

        QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm

        by Zacks Equity Research

        QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.

          Zacks Equity Research

          IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder

          by Zacks Equity Research

          IDEXX Laboratories (IDXX) already puts its Catalyst SDMA Test to use for hundreds of medical practices across the United States.

            Zacks Equity Research

            Boston Scientific Fortifies Pain Therapy Arm With FDA Nod

            by Zacks Equity Research

            Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.

              Zacks Equity Research

              Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq

              by Zacks Equity Research

              Illumina (ILMN) consistently tries to enhance NGS platform.

                Zacks Equity Research

                Express Scripts 90-Day Analysis of Opioid Management Positive

                by Zacks Equity Research

                Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.

                  Zacks Equity Research

                  Henry Schein (HSIC) Buys ABASE, Expands in Animal Health

                  by Zacks Equity Research

                  Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.

                    Zacks Equity Research

                    Abaxis' Product Line Expansion Aids Growth, Rivalry Rife

                    by Zacks Equity Research

                    Abaxis' (ABAX) growing portfolio of rapid test menu and a strong performance in Veterinary consumables drive growth. Intense competition in both the Medical and Veterinary markets is a concern.

                      Zacks Equity Research

                      Stryker (SYK) Posts Upbeat Preliminary Sales Figure for Q4

                      by Zacks Equity Research

                      Stryker Corporation's (SYK) fourth quarter and 2017 preliminary net sales figures are encouraging, courtesy of balanced revenue growth in all business segments.

                        Zacks Equity Research

                        Integra LifeSciences Estimates Strong Revenue Figures for Q4

                        by Zacks Equity Research

                        Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.

                          Zacks Equity Research

                          Intuitive Surgical (ISRG) Upbeat on Q4 & 2017 Sales Results

                          by Zacks Equity Research

                          Intuitive Surgical (ISRG) optimistic about fourth-quarter and 2017 net sales outcome on revenue growth across all business segments.

                            Zacks Equity Research

                            Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales

                            by Zacks Equity Research

                            Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.

                              Zacks Equity Research

                              Pacific Biosciences Hurt by Competition in Niche Markets

                              by Zacks Equity Research

                              Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.

                                Zacks Equity Research

                                Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home

                                by Zacks Equity Research

                                Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.

                                  Zacks Equity Research

                                  Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher

                                  by Zacks Equity Research

                                  Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

                                    Zacks Equity Research

                                    Wright Medical Upbeat on Preliminary Q4 & 2017 Sales Results

                                    by Zacks Equity Research

                                    Wright Medical (WMGI) forecasts improved sales, despite a plunge in revenues generated from the lower extremities business in fourth-quarter fiscal 2017.

                                      Zacks Equity Research

                                      Phibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails

                                      by Zacks Equity Research

                                      Phibro's (PAHC) Animal Health segment has been a key contributor to growth over the last few quarters. MFA remains soft in the United States due to sales decline of medically important antimicrobials.

                                        Zacks Equity Research

                                        CVS Health's (CVS) Outlook for 2018 Cheered by Investors

                                        by Zacks Equity Research

                                        CVS Health (CVS) to witness increased cash flow of around $1.2 billion in 2018, courtesy the latest US Tax legislation.

                                          Zacks Equity Research

                                          McKesson Buys RxCrossroads from CVS Health for $735 Million

                                          by Zacks Equity Research

                                          McKesson (MCK) has been actively pursuing deals, divestitures and acquisitions to drive growth. The latest buyout will boost Specialty Health business.

                                            Zacks Equity Research

                                            Walgreens Boots (WBA) Tops Q1 Earnings, Margins Decline

                                            by Zacks Equity Research

                                            Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q1 on continued prescription growth and strength in the Retail Pharmacy USA division.

                                              Zacks Equity Research

                                              Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss

                                              by Zacks Equity Research

                                              Neogen (NEOG) rides high on balanced growth across all business segments in Q2.

                                                Zacks Equity Research

                                                LabCorp Grapples With Reimbursement Cuts, Stiff Competition

                                                by Zacks Equity Research

                                                LabCorp (LH) faces intense competition from hospital-affiliated labs, primarily on the basis of quality of service.

                                                  Zacks Equity Research

                                                  NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018

                                                  by Zacks Equity Research

                                                  NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.